Advanced search
Publication Cover
Blood Pressure Volume 12, 2003 - Issue 2
Submit an article Journal homepage
2,804
Views
346
CrossRef citations to date
0
Altmetric
Research Article

Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function

ELENA KASCHINA Institute of Pharmacology and Toxicology, Charité Hospital Humboldt University at Berlin Germany and German Institute for High Blood Pressure Research Heidelberg Germany
&
THOMAS UNGER Institute of Pharmacology and Toxicology, Charité Hospital Humboldt University at Berlin Germany and German Institute for High Blood Pressure Research Heidelberg Germany
Pages 70-88 | Published online: 08 Jul 2009

  • de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors [In Process Citation]. Pharmacol Rev 2000; 52: 415-72.
  • Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-6.
  • Sasaki K, Yamano Y, Bardhan S, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991; 351: 230-3.
  • Alien AM, Zhuo J, Mendelsohn FA. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol 1999; 10Suppl 11:823-9.
  • Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor IA and IB in mouse. Am J Physiol 1994; 267(2 Pt 1): E260-7.
  • Gasc JM, Shanmugam S, Sibony M, Corvol P. Tissue specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. Hypertension 1994; 24: 531-7.
  • Leung PS, Yao XQ, Chan HC, Fu LX, Wong PY. Differential gene expression of angiotensin II receptor subtypes in the epididymides of mature and immature rats. Life Sci 1998; 62: 461-8.
  • Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J Hypertens 2000; 13 (1 Pt 2): 31-8S.
  • Miyazaki Y, Ichikawa I. Role of the angiotensin receptor in the development of the mammalian kidney and urinary tract. Comp Biochem Physiol A MoI Integr Physiol 2001; 128: 89-97.
  • Matsubara H, Sugaya T, Murasawa S, et al. Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron 1998; 80: 25-34.
  • Ahmed A, Li XF, Shams M, et al. Localization of the angiotensin II and its receptor subtype expression in human endometrium and identification of a novel high-affinity angiotensin II binding site. J Clin Invest 1995; 96: 848-57.
  • Li X, Shams M, Zhu J, et al. Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants. J CHn Invest 1998; 101: 442-54.
  • AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7: 1003-9.
  • Bullock GR, Steyaert I, Bilbe G, et al. Distribution of type 1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 2001; 115: 117 24.
  • Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B, Reincke M. Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. CHn Endocrinol (Oxf) 2001; 54: 627-32.
  • Gupta M, Miller BA, Ahsan N, et al. Expression of angiotensin II type I receptor on erythroid progenitors of patients with post transplant erythrocytosis. Transplanta tion 2000; 70: 1188-94.
  • Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
  • Zhuo J, Moeller I, Jenkins T, et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998; 16 (12 Pt 2): 2027 37.
  • Ichiki T, Takeda K, Tokunou T, et al. Reactive oxygen species-mediated homologous downregulation of angio tensin II type 1 receptor mRNA by angiotensin II. Hypertension 2001; 37 (2 Part 2): 535-40.
  • Makita N, Iwai N, Inagami T, Badr KF. Two distinct pathways in the down-regulation of type-1 angiotension II receptor gene in rat glomerular mesangial cells. Biochem Biophys Res Commun 1992; 185: 142-6.
  • Naville D, Lebrethon MC, Kermabon AY, Rouer E, Benarous R, Saez JM. Characterization and regulation of the angiotensin II type-1 receptor (binding and mRNA) in human adrenal fasciculata-reticularis cells. FEBS Lett 1993; 321: 184-8.
  • Monti J, Schinke M, Bohm M, Ganten D, Bader M, Bricca G. Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN). Am J Physiol Regul Integr Comp Physiol 2001; 280: R233-40.
  • Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) down regulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 2001; 37: 1141-6.
  • Delia Bruna R, Ries S, Himmelstoss C, Kurtz A. Expression of cardiac angiotensin II AT1 receptor genes in rat hearts is regulated by steroids but not by angiotensin II. J Hypertens 1995; 13: 763-9.
  • Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98: 2453-60.
  • Wyse B, Sernia C. Growth hormone regulates AT-1a angiotensin receptors in astrocytes. Endocrinology 1997; 138: 4176-80.
  • Ichiki T, Usui M, Kato M, et al. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 1998; 31 (1 Pt 2): 342-8.
  • Guo DF, Inagami T. Epidermal growth factor-enhanced human angiotensin II type 1 receptor. Hypertension 1994; 23 (6 Pt 2): 1032-5.
  • Takeda K, Ichiki T, Funakoshi Y, Ito K, Takeshita A. Downregulation of angiotensin II type 1 receptor by all trans retinoic acid in vascular smooth muscle cells. Hypertension 2000; 35 (1 Pt 2): 297-302.
  • Nickenig G, Strehlow K, Wassmann S, et al. Differential effects of estrogen and progesterone on AT(1) receptor gene expression in vascular smooth muscle cells. Circula tion 2000; 102: 1828-33.
  • Du J, Meng XP, Delafontaine P. Transcriptional regulation of the insulin-like growth factor-I receptor gene: evidence for protein kinase C-dependent and -independent path ways. Endocrinology 1996; 137: 1378-84.
  • Du Y, Qiu J, Nelson SH, Wang DH. Regulation of type 1 ANG II receptor in vascular tissue: role of alphal adrenoreceptor. Am J Physiol 1997; 273 (4 Pt 2): R1224-9.
  • Llorens-Cortes C, Greenberg B, Huang H, Corvol P. Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase polymerase chain reaction analysis. Hypertension 1994; 24: 538-48.
  • Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995; 95: 46-54.
  • Zhu YC, Falkenhahn M, Franke F, et al. Expression of cardiac angiotensin-converting enzyme after myocardial infarction. Chung Kuo Yao Li Hsueh Pao 1999; 20: 97 102.
  • Yamamoto K, Masuyama T, Sakata Y, et al. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000; 47: 274-83.
  • Iwai N, Inagami T. Regulation of the expression of the rat angiotensin II receptor mRNA. Biochem Biophys Res Commun 1992; 182: 1094-9.
  • Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT1 receptor over-expression in hypercho lesterolaemia. Ann Med 2000; 32: 386-9.
  • Bucher M, Inner KP, Hobbhahn J, Taeger K, Kurtz A. Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension 2001; 38: 177-82.
  • Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-72.
  • Blume A, Herdegen T, Unger T. Angiotensin peptides and inducible transcription factors. J MoI Med 1999; 77: 339 57.
  • Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. Angiotensin II stimulates sis-inducing factor like DNA binding activity. Evidence that the AT1A receptor activates transcription factor-Stat91 and/or a related protein. J Biol Chem 1994; 269: 31443-9.
  • Omura T, Yoshiyama M, Ishikura F, et al. Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J MoI Cell Cardiol 2001; 33: 307-16.
  • Mascareno E, Siddiqui MA. The role of Jak/STAT signaling in heart tissue renin-angiotensin system. MoI Cell Biochem 2000; 212: 171-5.
  • Lebrun CJ, Blume A, Herdegen T, Scifert K, Bravo R, Unger T. Angiotensin II induces a complex activation of transcription factors in the rat brain: expression of Fos, Jun and Krox proteins. Neuroscience 1995; 65: 93-9.
  • Blume A, Lebrun CJ, Herdegen T, et al. Increased brain transcription factor expression by angiotensin in genetic hypertension. Hypertension 1997; 29: 592-8.
  • Moellenhoff E, Blume A, Oilman J, et al. Effect of repetitive icv injections of ANG II on c-Fos and AT(1) receptor expression in the rat brain. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1095-104.
  • Dubey RK, Jackson EK, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens 1997; 6: 88-105.
  • Force T, Bonventre JV. Growth factors and mitogen activated protein kinases. Hypertension 1998; 31 (1 Pt 2): 152-61.
  • Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple automne growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-74.
  • Grafe M, Auch-Schwelk W, Zakrzewicz A, et al. Angiotensin Il-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997;81:804-11.
  • Hsueh WA, Law RE, Do YS. Integrins, adhesion, and cardiac remodeling. Hypertension 1998; 31 (1 Pt 2): 176 80.
  • Chen LS, Cuddy MP, LaVallette LA. Regulation of human renin gene promoter activity: a new negative regulatory region determines the responsiveness to TNF alpha. Kidney Int 1998; 54: 2045-55.
  • Bonventre JV. Phospholipase A2 and signal transduction. J Am Soc Nephrol 1992; 3: 128-50.
  • Pueyo ME, N'Diaye N, Michel JB. Angiotensin JJ-elicited signal transduction via AT1 receptors in endothelial cells. Br J Pharmacol 1996; 118: 79-84.
  • Freeman EJ, Ruehr ML, Dorman RV. ANG II-induced translocation of cytosolic PLA2 to the nucleus in vascular smooth muscle cells. Am J Physiol 1998; 274 (1 Pt 1): C282-8.
  • Dulin NO, Alexander LD, Harwalkar S, Falck JR, Douglas JG. Phospholipase A2-mediated activation of mitogen- activated protein kinase by angiotensin II. Proc Natl Acad Sci USA 1998; 95: 8098-102.
  • Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell MoI Physiol 2000; 279: L1005-28.
  • Griendling KK, Minier! CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
  • Zafari AM, Ushio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II induced vascular hypertrophy. Hypertension 1998; 32: 488-95.
  • Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II mediated hypertension in the rat increases vascular super oxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23.
  • Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vase Biol 1999; 19: 1623-9.
  • Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Ar terioscler Thromb Vase Biol 2000; 20: 645-51.
  • Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J 2000; 139 (1 Pt 2): S2-8.
  • Laragh JH. Two forms of vasoconstriction in systemic hypertension. Am J Cardiol 1987; 60: 82-93G.
  • Hahn AW, Resink TJ, Kern F, Buhler FR. Peptide vasoconstrictors, vessel structure, and vascular smooth muscle proliferation. J Cardiovasc Pharmacol 1993; 22 Suppl 5: S37-43.
  • Ito M, Oliverio MI, Mannon PJ, et al. Regulation of blood pressure by the type IA angiotensin II receptor gene. Proc Natl Acad Sci USA 1995; 92: 3521-5.
  • Oliverio MI, Best CF, Kirn HS, Arendshorst WJ, Smithies O, Coffman TM. Angiotensin II responses in AT1A receptor-deficient mice: a role for AT 1B receptors in blood pressure regulation. Am J Physiol 1997; 272 (4 Pt 2): F515-20.
  • Culmann J, Baulmann J, Blume A, Unger T. The renin angiotensin system in the brain: an update. JRAAS 2001; 2: 96-102.
  • Szabo Z, Speth RC, Brown PR, et al. Use of positron emission tomography to study AT1 receptor regulation in vivo. J Am Soc Nephrol 2001; 12: 1350-8.
  • Chung O, Unger T. Angiotensin II receptors in the kidney. Kidney Blood Press Res 1998; 21: 245-8.
  • Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
  • Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 1998; 54: 1390-1.
  • Bait JC, Mathy MJ, Nap A, Pfaffendorf M, van Zwieten PA. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin Il-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol 2001; 38: 141-8.
  • Kawai H, Stevens SY, Liang CS. Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2000; 279: H3012-9.
  • Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci USA 1997; 94: 6391-6.
  • Anvari A, Mast F, Schmidinger H, Schuster E, Allessie M. Effects of lidocaine, ajmaline, and diltiazem on ventricular defibrillation energy requirements in isolated rabbit heart. J Cardiovasc Pharmacol 1997; 29: 429-35.
  • Kaschina E, Blume A, Sandmann S, Unger Th. Angio tensin II up-regulates sodium-calcium exchanger in the rat heart after myocardial infarction via the AT1 receptor. J Hypertens 2001; 19 Suppl 2: S6.
  • Tokioka-Akagi T, Fujimori A, Shibasaki M, Inagaki O, Yanagisawa I. Comparison of the angiotensin II type 1 receptor antagonist YM3S8 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload. Jpn J Pharmacol 2001; 86: 79-85.
  • Sanada S, Kitakaze M, Node K, et al. Differential subcellular actions of ace inhibitors and at(l) receptor antagonists on cardiac remodeling induced by chronic inhibition of no synthesis in rats. Hypertension 2001; 38: 404-11.
  • Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-76.
  • Sasamura H, Shimizu-Hirota R, Nakaya H, Saruta T. Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats. Hypertens Res 2001; 24: 165-72.
  • Fischer JW, Stall M, Hahn AW, Unger T. Differential regulation of thrombospondin-1 and flbronectin by angio tensin II receptor subtypes in cultured endothelial cells. Cardiovasc Res 2001; 51: 784-91.
  • Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 251-9.
  • Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45: 419-29.
  • Chen HC, Bouchie JL, Ferez AS, et al. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-I gene expression. Arterioscler Thromb Vase Biol 2000; 20: 2297-302.
  • Goodfleld NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-5.
  • Vaughan DE. AT(1) receptor blockade and atherosclerosis: hopeful insights into vascular protection. Circulation 2000; 101: 1496-7.
  • Chen H, Li D, Sawamura T, Inoue K, Mehta JL. Upregulation of LOX-1 expression in aorta of hypercho lesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 2000; 276: 1100-4.
  • Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circula tion 2000; 101: 1586-93.
  • Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens 1999; 17 (12 Pt 2): 1775-86.
  • Blume A, Kaschina E, Unger T. Angiotensin II type 2 receptors: signalling and pathophysiological role. Curr Opin Nephrol Hypertens 2001; 10: 239-46.
  • Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991; 88: 921-33.
  • Shanmugam S, Lenkei ZG, Gasc JM, Corvol PL, Llorens Cortes CM. Ontogeny of angiotensin II type 2 (AT2) receptor mRNA in the rat. Kidney Int 1995; 47: 1095-100.
  • Lenkei Z, Palkovits M, Corvol P, Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 1997; 18: 383-439.
  • Wang ZQ, Moore AF, Ozono R, Siragy HM, Carey RM. Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. Hypertension 1998; 32:78-83.
  • Busche S, Gallinat S, Bohle RM, et al. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am J Pathol 2000; 157:605-11.
  • Miyata N, Park F, Li XF, Cowley AW, Jr. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol 1999; 277 (3 Pt 2): F437-46.
  • Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and rnal function. Hypertension 2000; 35 (1 Pt 2): 155-63.
  • Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663-7.
  • Ohkubo N, Matsubara H, Nozawa Y, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathie hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-62.
  • Bautista R, Sanchez A, Hernandez J, Oyekan A, Escalante B. Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension 2001; 38 (3 Pt 2): 669-73.
  • Makino I, Shibata K, Ohgami Y, Fujiwara M, Furukawa T. Transient upregulation of the AT2 receptor mRNA level after global ischemia in the rat brain. Neuropeptides 1996; 30:596-601.
  • Gallinat S, Yu M, Dorst A, Unger T, Herdegen T. Sciatic nerve transaction evokes lasting up-regulation of angio tensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res MoI Brain Res 1998; 57: 111-22.
  • Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998; 188: 661-70.
  • Luther C, Bohle R-M, Fine L, et al. Expression of angiotensin AT1 and AT2 receotors in heartcells after myocardial infarction. Hypertension 2000; 36: 655.
  • Sumners C, Myers LM. Angiotensin II decreases cGMP levels in neuronal cultures from rat brain. Am J Physiol 1991; 260 (1 Pt 1): C79-87.
  • Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M. Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. J CHn Invest 1994; 93: 1592-601.
  • Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibi tion of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-7.
  • Tsutsumi K, Stromberg C, Viswanathan M, Saavedra JM. Angiotensin- II receptor subtypes in fetal tissue of the rat: autoradiography, guanine nucleotide sensitivity, and asso ciation with phosphoinositide hydrolysis. Endocrinology 1991; 129: 1075-82.
  • Johnson MC, Aguilera G. Angiotensin-II receptor subtypes and coupling to signaling systems in cultured fetal fibroblasts. Endocrinology 1991; 129: 1266-74.
  • Speth RC, Kim KH. Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II. Biochem Biophys Res Commun 1990; 169: 997-1006.
  • Dudley DT, Hubbell SE, Summerfelt RM. Characterization of angiotensin II (2) binding sites in R3T3 cells. MoI Pharmacol 1991; 40: 360-7.
  • Csikos T, Balmforth AJ, Grojec M, Gohlke P, Oilman J, Unger T. Angiotensin AT2 receptor degradation is prevented by ligand occupation. Biochem Biophys Res Commun 1998; 243: 142-7.
  • Buisson B, Bottari SP, de Gasparo M, Gallo-Payet N, Payet MD. The angiotensin AT2 receptor modulates T-type calcium current in non-differentiated NG108-15 cells. FEBS Lett 1992; 309: 161-4.
  • Kijima K, Matsubara H, Murasawa S, et al. Regulation of angiotensin II type 2 receptor gene by the protein kinase C calcium pathway. Hypertension 1996; 27 (3 Pt 2): 529-34.
  • Matsubara H, Inada M. Molecular insights into angiotensin II type 1 and type 2 receptors: expression, signaling and physiological function and clinical application of its antagonists. Endocr J 1998; 45: 137-50.
  • Ichiki T, Inagami T. Transcriptional regulation of the mouse angiotensin II type 2 receptor gene. Hypertension 1995; 25 (4 Pt 2): 720-5.
  • Mancina R, Susini T, Renzetti A, et al. Sex steroid modulation of AT2 receptors in human myometrium. J CHn Endocrinol Metab 1996; 81: 1753-7.
  • Wang DH, Qiu J, Hu Z. Differential regulation of angiotensin II receptor subtypes in the adrenal gland: role of aldosterone. Hypertension 1998; 32: 65-70.
  • Bonnet F, Cooper ME, Carey RM, Casley D, Cao Z. Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion. J Hypertens 2001; 19: 1075-81.
  • Nouet I, Nahmias I. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 2000; 11: 1-6.
  • Huang XC, Sumners C, Richards EM. Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. Adv Exp Med Biol 1996; 396: 209-15.
  • Horiuchi M, Akishita M, Dzau VJ. Molecular and cellular mechanism of angiotensin II-mediated apoptosis. Endocr Res 1998; 24: 307-14.
  • Lehtonen JY, Daviet L, Nahmias C, Horiuchi M, Dzau VJ. Analysis of functional domains of angiotensin II type 2 receptor involved in apoptosis. MoI Endocrinol 1999; 13: 1051-60.
  • Stroth U, Blume A, Mielke K, Unger T. Angiotensin AT(2) receptor stimulates ERKl and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Brain Res MoI Brain Res 2000; 78: 175-80.
  • Haithcock D, Jiao H, Cui XL, Hopfer U, Douglas JG. Renal proximal tubular AT2 receptor: signaling and transport. J Am Soc Nephrol 1999; 10 Suppl 11: S69-74.
  • Kohout, Rogers Angiotensin II activates the Na+/HCO3- symport through a phosphoinositide-independent mechanism in cardiac cells. 1995; 270: 20432-8J Biol Chem
  • Sandmann, Yu, Kaschina Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na + -H + exchanger and Na + -HCO3 − symporter in the rat heart after myocardial infarction. 2001; 37: 2154-65J Am Coll Cardiol
  • Gallinat S, Busche S, Schutze S, Kranke M, Unger T. AT2 receptor stimulation induces generation of ceramides in PC12W cells. FEBS Lett 1999; 443: 75-9.
  • Lehtonen JY, Horiuchi M, Daviet L, Akishita M, Dzau VJ. Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 1999; 274: 16901-6.
  • Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kranke M. TNF activates NF-kappa B by phosphatidylcholine-speciflc phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992; 71: 765 76.
  • Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms [see com ments]. Circ Res 2000; 86: 1266-72.
  • Wiemer G, Scholkens BA, Wagner A, Heitsch H, Linz W. The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischmie rat hearts. J Hypertens Suppl 1993; 11 Suppl 5: S234-5.
  • Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J CHn Invest 1997; 99: 1926-35.
  • Siragy HM, Jaffa AA, Margolius HS, Carey RM. Renin angiotensin system modulates renal bradykinin production. Am J Physiol 1996; 271 (4 Pt 2): R1090-5.
  • Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin dependent mechanism. Hypertension 1998; 31 (1 Pt 2): 349-55.
  • Sosa-Canache B, Cierco M, Gutierrez CI, Israel A. Role of bradykinins and nitric oxide in the AT2 receptor-mediated hypotension. J Hum Hypertens 2000; 14 Suppl 1: S40-6.
  • Israel A, Cierco M, Sosa B. Angiotensin AT(2) receptors mediate vasodepressor response to footshock in rats. Role of kinins, nitric oxide and prostaglandins. Eur J Pharmacol 2000; 394: 103-8.
  • Gironacci MM, Vatta M, Rodriguez-Fermepin M, Fernan dez BE, Pena C. Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypotha lamus. Hypertension 2000; 35: 1248-52.
  • Lambers DS, Greenberg SG, Clark KE. Functional role of angiotensin II type 1 and 2 receptors in regulation of uterine blood flow in nonpregnant sheep. Am J Physiol Heart Circ Physiol 2000; 278: H353-9.
  • Stall M, Hahn A, Jonas U, Zhao Y, Schieffer B, Fischer J, Unger Th. Identification of a zincfinger homoedomain enhancer protein following AT2 receptor stimulation by differential mRNA display. Arterioscler Throm Vase Biol 2002; 22: 231-7.
  • Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice [published erratum appears in Nature 1996; 380: 366]. Nature 1995; 377: 744-7.
  • Nishimura H, Yerkes E, Hohenfellner K, et tu. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. MoI Cell 1999; 3: 1-10.
  • Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96: 6506-10.
  • Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation [see comments]. J Clin Invest 1999; 104: 925-35.
  • Ichihara S, Senbonmatsu T, Price E, Jr, Ichiki T, Gaffhey FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001; 104: 346-51.
  • Sakagawa T, Okuyama S, Kawashima N, et al. Pain threshold, learning and formation of brain edema in mice lacking the angiotensin II type 2 receptor. Life Sci 2000; 67: 2577-85.
  • Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93: 156-60.
  • Tanaka M, Ohnishi J, Ozawa Y, et al. Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Commun 1995; 207: 593-8.
  • Li W, Ye Y, Fu B, et al. Genetic deletion of AT2 receptor antagonizes angiotensin II-induced apoptosis in fibroblasts of the mouse embryo. Biochem Biophys Res Commun 1998; 250: 72-6.
  • Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothe lial cells. Protective effect of nitric oxide. Circ Res 1997; 81:970-6.
  • Shenoy UV, Richards EM, Huang XC, Sumners C. Angiotensin II type 2 receptor-mediated apoptosis of cultured neurons from newborn rat brain. Endocrinology 1999; 140: 500-9.
  • Chamoux E, Breault L, Lehoux JG, Gallo-Payet N. Involvement of the angiotensin II type 2 receptor in apoptosis during human fetal adrenal gland development. J CHn Endocrinol Metab 1999; 84: 4722-30.
  • Tea BS, Der Sarkissian S, Touyz RM, Hamet P, deBlois D. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension 2000; 35: 1069-73.
  • Zhu YZ, Chimon GN, Zhu YC, et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 2000; 11: 1191-4.
  • Miura S, Karnik SS. Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis [In Process Citation]. Embo J 2000; 19: 4026-35.
  • Stall M, Unger T. Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept 2001; 99: 175-82.
  • Wilson DP, Saward L, Zahradka P, Cheung PK. Angio tensin II receptor antagonists prevent neointimal prolifera tion in a porcine coronary artery organ culture model. Cardiovasc Res 1999; 42: 761-72.
  • Laflamme L, Gasparo M, Gallo JM, Payet MD, Gallo Payet N. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem 1996; 271: 22729-35.
  • Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. MoI Cell Endocrinol 1996; 122: 59-67.
  • Tsuzuki S, Eguchi S, Inagami T. Inhibition of cell proliferation and activation of protein tyrosine phosphatase mediated by angiotensin II type 2 (AT2) receptor in R3T3 cells. Biochem Biophys Res Commun 1996; 228: 825-30.
  • Goto M, Mukoyama M, Suga S, et al. Growth-dependent induction of angiotensin II type 2 receptor in rat mesangial cells. Hypertension 1997; 30 (3 Pt 1): 358-62.
  • Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27 (3 Pt 2): 760-5.
  • Gallinat S, Csikos T, Meffert S, Herdegen T, Stoll M, Unger T. The angiotensin AT2 receptor down-regulates neurofilament M in PCl 2W cells. Neurosci Lett 1997; 227: 29-32.
  • Stroth U, Meffert S, Gallinat S, Unger T. Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. Brain Res MoI Brain Res 1998; 53: 187-95.
  • Buisson B, Laflamme L, Bottari SP, de Gasparo M, Gallo Payet N, Payet MD. A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells. J Biol Chem 1995; 270: 1670-4.
  • Yamada H, Akishita M, Ito M, et al. AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 1999; 33: 1414-9.
  • Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999; 274: 31686 92.
  • Yi Zhac, Biermann T, Biermann T, Luther C, Unger Th, Gohlke P. Contribution of bradykinin and nitric oxide to the AT2 receptor-mediated differentiation in PC 12W cells. J Neurochemistry, in press.
  • Bleuel A, de Gasparo M, Whitebread S, Puttner I, Monard D. Regulation of protease nexin-1 expression in cultured Schwann cells is mediated by angiotensin II receptors. J Neurosci 1995; 15 (1 Pt 2): 750-61.
  • Reinecke K, Lucius R, Herdegen T, Unger Th. Angiotensin II increases the rate of functional regeneration in the rat sciatic nerve. Hypertension 2000; 36: 658.
  • Dai WJ, Funk A, Herdegen T, Unger T, Oilman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30: 2391-8; discussion 2398-9.
  • Oilman J, von Heyer C, Piepenburg B, Rascher W, Unger T. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol 1999; 367: 255-65.
  • Kimura B, Sumners C, Phillips MI. Changes in skin angiotensin II receptors in rats during wound healing. Biochem Biophys Res Commun 1992; 187: 1083-90.
  • Ichiki T, Kambayashi Y, Inagami T. Multiple growth factors modulate mRNA expression of angiotensin II type 2 receptor in R3T3 cells. Circ Res 1995; 77: 1070-6.
  • Konstam MA, Patten RD, Thomas I, et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000; 139: 1081-7.
  • Tsutsumi Y, Matsubara H, Ohkubo N, et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac flbroblasts are the major cell type for its expression. Circ Res 1998; 83: 1035-46.
  • Matsumoto T, Ozono R, Oshima T, et al. Type 2 angiotensin II receptor is downregulated in cardiomyocytes of patients with heart failure. Cardiovasc Res 2000; 46:73 81.
  • Cerbai E, Crucitti A, Sartiani L, et al. Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes. Cardiovasc Res 2000; 45: 388-96.
  • Yamazaki T, Komuro I, Shiojima I, Yazaki Y. The molecular mechanism of cardiac hypertrophy and failure. Ann NY Acad Sci 1999; 874: 38-48.
  • Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Lorell BH. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation 1999; 99: 22-5.
  • Senbonmatsu T, Ichihara S, Price E, Jr, Gaffney FA, Inagami T. Evidence for angiotensin II type 2 receptor mediated cardiac myocyte enlargement during in vivo pressure overload [In Process Citation]. J Clin Invest 2000; 106: R1-5.
  • Schmieder, Erdmann, Delles Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. 2001; 37: 175-82J Am Coll Cardiol
  • Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999; 33: 1237-42.
  • Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999; 34: 1112-6.
  • Guron G, Friberg P. An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 2000; 18: 123-37.
  • Lo M, Liu KL, Lantelme P, Sassard J. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 1995; 95: 1394-7.
  • Arima S, Ito S. Angiotensin U type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vaso dilatation [editorial]. Nephrol Dial Transplant 2000; 15: 448-51.
  • Kohagura K, Endo Y, Ito O, Arima S, Omata K, Ito S. Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol Scand 2000; 168: 107-12.
  • Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA. Angiotensin II releases 20-HETE from rat renal micro vessels. Am J Physiol Renal Physiol 2000; 279: F544-51.
  • Sadoshima J. Cytokine actions of angiotensin II [editorial; comment]. Circ Res 2000; 86: 1187-9.
  • Moser M. Update on the management of hypertension: do recent clinical trial results indicate a change in national recommendations for therapy? J CHn Hypertens (Green wich) 2002; 4 Suppl 2: 20-31.
  • Hedner T. The problem of hypertension in the elderly. Blood Press Suppl 2000; 2: 4-6.
  • Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-92.
  • Vivian EM, Rubinstein GB. Pharmacologie management of diabetic nephropathy. Clin Ther 2002; 24: 1741-56; discussion 1719.
  • Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-81.
  • Bojovic L, Micic D. Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension. Med Pregl 2002; 55: 286-92.
  • Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002; 62: 1381-405.
  • Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemie Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischmie heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058-63.
  • Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1: 18-20.
  • Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSEN SUS Trial Study Group. N Engl J Med 1987; 316:1429-35.
  • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293 302.
  • Cohn JN. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure. Herz 1991; 16 Spec No 1: 267-71.
  • Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
  • Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.
  • Ball SG. Early or late ACE inhibition after myocardial infarction. JCardiovasc Pharmacol 1993; 22 Suppl 9: S18 21.
  • Kirch W, Horn B, Schweizer J. Comparison of angiotensin II receptor antagonists. Eur J Clin Invest 2001; 31: 698 706.
  • Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10 Suppl 1:6-11.
  • Chimg O, Unger T. Pharmacology of angiotensin receptors and AT1 receptor blockers. Basic Res Cardiol 1998; 93 Suppl 2: 15-23.
  • Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM. Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol 2001; 24: 183 90.
  • Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovas cular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995 1003.
  • Mann J, Julius S. The Valsartan Antihypertensive Long term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7: 176-83.
  • Hansson L, Lithell H, Skoog I, et al. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline charac teristics. Blood Press 2000; 9: 146-51.
  • Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-8.
  • Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
  • Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
  • Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999; 83: 477-81.
  • Pfeffer MA. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000; 139 (1 Pt 2): S23-8.
  • Boucher M, Ma J. Heart failure: is there a role for angiotensin II receptor blockers? Issues Emerg Health Technol 2002: 1-4.
  • Murray DR, Dugan J. Overview of recent clinical trials in heart failure: what is the current standard of care? Cardiol Rev 2000; 8: 340-7.
  • Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Pro gramme Investigators. J Card Fail 1999; 5: 276-82.
  • McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.
  • Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89: 18A-25A; discussion 25-6A.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.